A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction.
Eur J of Heart Failure. 2017 Jul 5.
This study was designed to evaluate the safety, tolerability and haemodynamic effects of BMS‐986231, a novel second‐generation nitroxyl donor with potential inotropic, lusitropic and vasodilatory effects in patients hospitalized with decompensated heart failure and reduced ejection fraction (HFrEF).
Authors: Tita C, Gilbert EM, Van Bakel AB, Grzybowski J,
Haas GJ, Jarrah M, Dunlap SH, Gottlieb SS, Klapholz M,
Patel PC, Pfister R, Seidler T, Shah KB, Zieliński T, Venuti RP,
Cowart D, Foo SY, Vishnevsky A, Mitrovic V